Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 25

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 25
---
 with sufficient clinical or commercial quantities of such product candidates or          
 products, fails to do so at acceptable quality levels or prices or fails to achieve or maintain satisfactory regulatory compliance.             |

| • | We are dependent on third party suppliers, and if we experience problems with any of these third parties, 
 the manufacturing of our product candidates could be delayed, which could harm our results of operations. |

| • | If we cannot meet NASDAQ’s continued listing requirements, NASDAQ may delist our Depositary Shares, 
 which could have an adverse impact on the liquidity and market price of our Depositary Shares.      |

| • | The price of our Depositary Shares may be volatile. |

| • | The liquidity of our Depositary Shares may have an adverse effect on share price. |

| • | Shareholder ownership interests in the Company may be diluted as a result of, among other things, future                  
 financings and/or additional acquisitions, and may have a material negative effect on the market price of our securities. |

| • | Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. |

| • | As a foreign private issuer, we are not required to comply with many of the corporate governance standards 
 of NASDAQ applicable to companies incorporated in the United States.                                       |

| • | Your right to participate in any future rights offerings may be limited, which may cause dilution to your holdings. |

| • | Protections found in provisions under the United Kingdom City Code on Takeovers and Mergers may delay                                
 or discourage a takeover attempt, including attempts that may be beneficial to holders of our Ordinary Shares and Depositary Shares. |

| 14 |

Risks Related to the Equity Financing

It is not possible to predict the actual number of Depositary Shares, if any, we will sell under the Purchase Agreement, or the actual gross proceeds resulting from those sales or the dilution to you from those sales.

Pursuant to the Purchase Agreement,
the Selling Shareholder shall, subject to the restrictions and satisfaction of the conditions in the Purchase Agreement, purchase from
us up to $35.0 million of Depositary Shares, upon the terms and subject to the conditions and limitations set forth in the Purchase Agreement,
or the Commitment Amount, and, accordingly, we have registered 350,000,000,000 Ordinary Shares represented by 35,000,000 Depositary Shares
for issuance under the Purchase Agreement and resale pursuant to this prospectus, assuming that that $35.0 million